Solid-state transformation of different gabapentin polymorphs upon milling and co-milling

International Journal of Pharmaceutics

Volumn 396, Issue 1-2, 2010, Pages 83-90

  Lin, Shan Yang ^a   Hsu, Cheng Hung ^b   Ke, Wen Ting ^b  

^a YUANPEI UNIVERSITY   (Taiwan)

^b Depart Res and Develop   (Taiwan)

Author keywords

Additives; Co milling; Gabapentin; Milling; Polymorphic transition

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; AEROSIL; BETA CYCLODEXTRIN; CALCIUM PHOSPHATE DIBASIC; DEXTRIN; DRUG ADDITIVE; GABAPENTIN; GELATIN; HYDROXYPROPYLMETHYLCELLULOSE; MAGNESIUM STEARATE; MANNITOL; MICROCRYSTALLINE CELLULOSE; POVIDONE; STARCH; TALC; 4 AMINOBUTYRIC ACID; AMINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; EXCIPIENT; WATER;

ARTICLE; DRUG STABILITY; INFRARED SPECTROSCOPY; MILLING; PRIORITY JOURNAL; SOLID STATE; TABLET MANUFACTURE; CHEMISTRY; CRYSTALLIZATION; MEDICINAL CHEMISTRY; MICROSPECTROPHOTOMETRY; PHARMACEUTICS; PROCEDURES; TIME;

AMINES; ANALGESICS; ANTICONVULSANTS; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; CYCLOHEXANECARBOXYLIC ACIDS; DRUG STABILITY; EXCIPIENTS; GAMMA-AMINOBUTYRIC ACID; MICROSPECTROPHOTOMETRY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS; WATER;

EID: 77955056024     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.06.014     Document Type: Article

References (44)

1. Ainouz A., Authelin J.R., Billot P., Lieberman H. Modeling and prediction of cocrystal phase diagrams. Int. J. Pharm. 2009, 374:82-89.
2. Atkinson M.B.J., Bucar D.K., Sokolov A.N., Friscic T., Robinson C.N., Bilal M.Y., Sinada N.G., Chevannes A., MacGillivray L.R. General application of mechanochemistry to templated solid-state reactivity: rapid and solvent-free access to crystalline supermolecules. Chem. Commun. 2008, 44:5713-5715.
3. Bahl D., Hudak J., Bogner R.H. Comparison of the ability of various pharmaceutical silicates to amorphize and enhance dissolution of indomethacin upon co-grinding. Pharm. Dev. Technol. 2008, 13:255-269.
4. Bailey A.G. Electrostatic phenomena during powder handling. Powder Technol. 1984, 37:71-85.
5. Balani P.N., Ng W.K., Tan R.B., Chan S.Y. Influence of excipients in comilling on mitigating milling-induced amorphization or structural disorder of crystalline pharmaceutical actives. J. Pharm. Sci. 2010, 99:2462-2474.
6. Barzegar-Jalali M., Valizadeh H., Shadbad M.R., Adibkia K., Mohammadi G., Farahani A., Arash Z., Nokhodchi A. Cogrinding as an approach to enhance dissolution rate of a poorly water-soluble drug (gliclazide). Powder Technol. 2010, 197:150-158.
7. Braga D., Grepioni F., Maini L., Rubini K., Polito M., Brescello R., Cotarca L., Duarte M.T., André V., Piedade M.F.M. Polymorphic gabapent thermal behaviour reactivity interconversion of forms in solution solid-state. New J. Chem. 2008, 32:1788-1795.
8. Brittain H.G., Fiese E.F. Effects of pharmaceutical processing on drug polymorphs and solvates. Polymorphism in Pharmaceutical Solids 1999, 331-361. Marcel Dekker, New York. H.G. Brittain (Ed.).
9. Byrn S.R., Pfeiffer R.R., Stowell J.G. Solid-State Chemistry of Drugs 1999, SSCI Inc., West Lafayette, IN, USA. 2nd edn.
10. Brittain H.G. Effects of mechanical processing on phase composition. J. Pharm. Sci. 2002, 91:1573-1580.
11. Chaumeil J.C. Micronization: a method of improving the bioavailability of poorly soluble drugs. Method Find. Exp. Clin. Pharmacol. 1998, 20:211-215.
12. Chawla G., Bansal A.K. Challenges in polymorphism of pharmaceuticals. CRIPS 2004, 5:5-12.
13. Chimatadara S.A., Basavaraja T., Thabaja K.A., Sharanappa T. Ruthenium(III) catalysed oxidation of gabapentin (neurontin) by diperiodatocuprate(III) in aqueous alkaline medium: a kinetic and mechanistic study. J. Mol. Catal. A: Chem. 2007, 267:65-71.
14. Ciavarella A.B., Gupta A., Sayeed V.A., Khan M.A., Faustino P.J. Development and application of a validated HPLC method for the determination of gabapentin and its major degradation impurity in drug products. J. Pharm. Biomed. Anal. 2007, 43:1647-1653.
15. Colombo I., Grassi G., Grassi M. Drug mechanochemical activation. J. Pharm. Sci. 2009, 98:3961-3986.
16. Datta S., Grant D.J.W. Crystal structures of drugs: advances in determination, prediction and engineering. Nat. Rev. Drug Discov. 2004, 3:42-57.
17. Descamps M., Willart J.F., Dudognon E., Lefort R., Desprez S., Caron V. Phase transformations induced by grinding: what is revealed by molecular materials. Mater. Res. Soc. Symp. Proc. 2007, 979:116-131.
18. Descamps M., Willart J.F., Dudognon E., Caron V. Transformation of pharmaceutical compounds upon milling and comilling: the role of Tg. J. Pharm. Sci. 2007, 96:1398-1407.
19. Friscić T., Jones W. Recent advances in understanding the mechanism of cocrystal formation via grinding. Cryst. Growth Des. 2009, 9:1621-1637.
20. Dobecki D.A., Schocket S.M., Wallace M.S. Update on pharmacotherapy guidelines for the treatment of neuropathic pain. Curr. Pain Headache Rep. 2006, 10:185-190.
21. Goa K.L., Sorkin E.M. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993, 46:409-427.
22. Hsu C.H., Lin S.Y. Rapid examination of the kinetic process of intramolecular lactamization of gabapentin using DSC-FTIR. Thermochim. Acta 2009, 486:5-10.
23. Hsu C.H., Ke W.T., Lin S.Y. Progressive steps of polymorphic transformation of gabapentin polymorphs studied by hot-stage FTIR microspectroscopy. J. Pharm. Pharmaceut. Sci. 2010, 13:67-77.
24. Kesisoglou F., Panmai S., Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 2007, 59:631-644.
25. Lin S.Y., Chien J.L. In vitro simulation of solid-solid dehydration, rehydration, and solidification of trehalose dihydrate using thermal and vibrational spectroscopic techniques. Pharm. Res. 2003, 20:1926-1931.
26. Lin S.Y., Cheng W.T., Wang S.L. Thermodynamic and kinetic characterization of polymorphic transformation of famotidine during grinding. Int. J. Pharm. 2006, 318:86-91.
27. Lin S.Y., Cheng W.T., Wang S.L. Thermal micro-Raman spectroscopic study of polymorphic transformation of famotidine under different compression pressures. J. Raman Spectrosc. 2007, 38:39-43.
28. Moretti R., Antonello R.M., Torre P., Cazzato G. Headache and neck pain: gabapentin as a possible treatment. J. Headache Pain 2000, 1:155-161.
29. Morris K.R., Griesser U.J., Eckhardt C.J., Stowell J.G. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv. Drug Deliv. Rev. 2001, 48:91-114.
30. Nokhodchi A., Okwudarue O.N., Valizadeh H., Momin M.N. Cogrinding as a tool to produce sustained release behavior for theophylline particles containing magnesium stearate. AAPS PharmSciTech. 2009, 10:1243-1251.
31. Oguchi T. Grinding process applied for pharmaceutical products. J. Pharm. Sci. Technol. (Jpn.) 2004, 64:59s-61s.
32. Pesachovich, M., Singer, C., Pilarski, G., 2001. Preparation of gabapentin. US Patent 6255526.
33. Ranpise N.S., Kulkarni N.S., Mair P.D., Ranade A.N. Improvement of water solubility and in vitro dissolution rate of aceclofenac by complexation with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin. Pharm. Dev. Technol. 2010, 15.
34. Rasenack N., Müller B.W. Micron-size drug particles: common and novel micronization techniques. Pharm. Dev. Technol. 2004, 9:1-13.
35. Reece H.A., Levendis D.C. Polymorphs of gabapentin. Acta Crystallogr. 2008, C64:o105-o108.
36. Satyanarayana, C., Ramanjaneyulu, G.S., Kumar, I.V.S., 2004. Novel polymorph of gabapentin and its conversion to gabapentin Form-II. WO 2004/110342.
37. Sills G.J. The mechanisms of action of gabapentin and pregabalin. Curr. Opin. Pharmacol. 2006, 6:108-113.
38. Wang S.L., Lin S.Y., Hsieh T.F., Chan S.A. Thermal behavior and thermal decarboxylation of 10-hydroxycamptothecin in the solid sate. J. Pharm. Biomed. Anal. 2007, 43:457-463.
39. Watanabe T., Hasegawa S., Wakiyama N., Kusai A., Senna M. Comparison between polyvinylpyrrolidone and silica nanoparticles as carriers for indomethacin in a solid state dispersion. Int. J. Pharm. 2003, 250:283-286.
40. Wongmekiat A., Tozuka Y., Moribe K., Oguchi T., Yamamoto K. Preparation of drug nanoparticles by co-grinding with cyclodextrin: formation mechanism and factors affecting nanoparticle formation. Chem. Pharm. Bull. (Tokyo) 2007, 55:359-363.
41. Vippagunta S.R., Brittain H.G., Grant D.J. Crystalline solids. Adv. Drug Deliv. Rev. 2001, 48:3-26.
42. Yildirim K., Deniz O., Gureser G., Karatay S., Ugur M., Erdal A., Senel K. Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. J. Back Musculoskelet. Rehabil. 2009, 22:17-20.
43. Yu L.X., Lionberger R.A., Raw A.S., D'Costa R., Wu H., Hussain A.S. Applications of process analytical technology to crystallization processes. Adv. Drug Deliv. Rev. 2004, 56:349-369.
44. Zour E., Lodhi S.A., Nesbitt R.U., Silbering S.B., Chaturvedi P.R. Stability studies of gabapentin in aqueous solutions. Pharm. Res. 1992, 9:595-600.